-
Heart pump increases survival in STEMI-related cardiogenic shock Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-23 Jennifer Harman
Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.
-
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-23 Karina Huynh
Three randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.
-
Sifting for Gold in Terabytes of Data: Illuminating Cardiovascular Biology in the ‘Omics Age Circulation (IF 37.8) Pub Date : 2024-04-22 Svati H. Shah, Robert E. Gerszten
Traditional scientific discovery has been flipped on its head, in large part because of enormous amounts of ‘omics data generated from human samples. Scientific discovery previously initiated in model systems has given way to a human-forward approach where genomic, proteomic, and metabolomic profiling (‘omics) is performed in thousands of biospecimens in just months. Such studies can facilitate mechanistic
-
Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-23 Gregory B. Lim
According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.
-
Strategies for the delivery of sex-based equity in cardiovascular clinical trials Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-23 Julie Sanders, Tim Clayton, Stacey Matthews, Sarah Murray, Lynn Laidlaw, Richard Evans, Rochelle Wynne
The under-representation of women in cardiovascular clinical trials persists across participant, clinician and research roles. This gap perpetuates health inequity and hampers the generation, translation and implementation of optimal evidence-based care. Urgent action is needed to address barriers, promote diversity, and ensure inclusive trial design and health-care delivery and dissemination, for
-
No benefit of β-blockers after myocardial infarction with preserved ejection fraction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-22 Gregory B. Lim
In the REDUCE-AMI trial, the use of β-blockers in patients with acute myocardial infarction (MI) who have undergone early coronary angiography and have a preserved left ventricular ejection fraction did not reduce the risk of death or new MI compared with no β-blocker use.
-
Autonomic Dysfunction Linked to Inhibition of the Nav1.7 Sodium Channel Circulation (IF 37.8) Pub Date : 2024-04-22 Christopher P. Regan, Pierre Morissette, Richard L. Kraus, Erjia Wang, Leticia Arrington, Marissa Vavrek, Jan de Hoon, Marleen Depre, Thomas Lodeweyck, Ignace Demeyer, Tine Laethem, Aubrey Stoch, Arie Struyk
Human genetic phenotypes associated with loss or gain of function implicate the Nav1.7 channel as a promising target for novel analgesics.1,2 However, the expression of NaV1.7 on autonomic afferent c-type fibers, on sympathetic efferent fibers, and cardiovascular–related autonomic adverse effects reported in gain-of-function mutation phenotypes2,3 create concern for potential Nav1.7 antagonists. Recent
-
Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-22 Jingrui Chen, Jing Wei, Peng Xia, Yuening Liu, Mahder Dawit Belew, Ryan Toohill, Boyang Jason Wu, Zhaokang Cheng
Aims The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that DOX-induced apoptosis is accompanied by cardiomyocyte cell cycle-reentry. Cell cycle progression requires cyclin-dependent kinase 7 (CDK7)-mediated activation of downstream cell cycle CDKs. This study aims to determine whether
-
Mechanisms of ischaemia-induced arrhythmias in hypertrophic cardiomyopathy: a large-scale computational study Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-22 James A Coleman, Ruben Doste, Zakariye Ashkir, Raffaele Coppini, Rafael Sachetto, Hugh Watkins, Betty Raman, Alfonso Bueno-Orovio
Aims Lethal arrhythmias in hypertrophic cardiomyopathy (HCM) are widely attributed to myocardial ischaemia and fibrosis. How these factors modulate arrhythmic risk remains largely unknown, especially as invasive mapping protocols are not routinely used in these patients. By leveraging multiscale digital-twin technologies, we aim to investigate ischaemic mechanisms of increased arrhythmic risk in HCM
-
Aquaporins enriched in endothelial vacuole membrane regulate the diameters of microvasculature in hyperglycemia Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-22 Changsheng Chen, Yinyin Qin, Yidan Xu, Xiaoning Wang, Wei Lei, Xiaozhong Shen, Lixun Chen, Linnong Wang, Jie Gong, Yongming Wang, Shijun Hu, Dong Liu
Background In patients with diabetic microvascular complications, decreased perfusion or vascular occlusion, caused by reduced vascular diameter, is a common characteristic that will lead to insufficient blood supply. Yet, the regulatory mechanism and effective treatment approach remain elusive. Methods and Results Our initial findings revealed a notable decrease in the expression of human AQP1 in
-
Single-Cell Gene-Regulatory Networks of Advanced Symptomatic Atherosclerosis Circ. Res. (IF 20.1) Pub Date : 2024-04-19 Giuseppe Mocci, Katyayani Sukhavasi, Tiit Örd, Sean Bankier, Prosanta Singha, Uma Thanigai Arasu, Olayinka Oluwasegun Agbabiaje, Petri Mäkinen, Lijiang Ma, Chani J. Hodonsky, Redouane Aherrahrou, Lars Muhl, Jianping Liu, Sonja Gustafsson, Byambajav Byandelger, Ying Wang, Simon Koplev, Urban Lendahl, Gary Owens, Nicholas J. Leeper, Gerard Pasterkamp, Michael Vanlandewijck, Tom Michoel, Arno Ruusalepp
BACKGROUND:While our understanding of the single-cell gene expression patterns underlying the transformation of vascular cell types during the progression of atherosclerosis is rapidly improving, the clinical and pathophysiological relevance of these changes remains poorly understood.METHODS:Single-cell RNA sequencing data generated with SmartSeq2 (≈8000 genes/cell) in nearly 19 000 single cells isolated
-
GLI1+ Cells Contribute to Vascular Remodeling in Pulmonary Hypertension Circ. Res. (IF 20.1) Pub Date : 2024-04-19 Xuran Chu, Vahid Kheirollahi, Arun Lingampally, Prakash Chelladurai, Chanil Valasarajan, Ana Ivonne Vazquez-Armendariz, Stefan Hadzic, Ali Khadim, Oleg Pak, Stefano Rivetti, Jochen Wilhelm, Marek Bartkuhn, Slaven Crnkovic, Alena Moiseenko, Monika Heiner, Simone Kraut, Leila Sotoodeh, Janine Koepke, Guilherme Valente, Clemens Ruppert, Thomas Braun, Christos Samakovlis, Ioannis Alexopoulos, Mario Looso
BACKGROUND:The precise origin of newly formed ACTA2+ (alpha smooth muscle actin-positive) cells appearing in nonmuscularized vessels in the context of pulmonary hypertension is still debatable although it is believed that they predominantly derive from preexisting vascular smooth muscle cells (VSMCs).METHODS:Gli1Cre-ERT2; tdTomatoflox mice were used to lineage trace GLI1+ (glioma-associated oncogene
-
NLRP3 inflammasome-mediated premature immunosenescence drives diabetic vascular aging dependent on the induction of perivascular adipose tissue dysfunction Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-21 Guang-Jie Tai, Yan-Jie Ma, Jun-Lin Feng, Jia-Peng Li, Shu Qiu, Qing-Qing Yu, Ren-Hua Liu, Silumbwe Ceaser Wankumbu, Xin Wang, Xiao-Xue Li, Ming Xu
Aims The vascular aging process accelerated by type 2 diabetes mellitus (T2DM) is responsible for the elevated risk of associated cardiovascular diseases (CVDs). Metabolic disorder-induced immune senescence has been implicated in multi-organ/tissue damage. Herein, we sought to determine the role of immunosenescence in diabetic vascular aging and to investigate the underlying mechanisms. Methods and
-
Self-expanding valves more beneficial than balloon-expandable valves in patients with a small aortic annulus Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-19 Karina Huynh
In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve.
-
Circular RNA circZFPM2 regulates cardiomyocyte hypertrophy and survival Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-04-19 Dimyana Neufeldt, Arne Schmidt, Elisa Mohr, Dongchao Lu, Shambhabi Chatterjee, Maximilian Fuchs, Ke Xiao, Wen Pan, Sarah Cushman, Christopher Jahn, Malte Juchem, Hannah Jill Hunkler, Giuseppe Cipriano, Bjarne Jürgens, Kevin Schmidt, Sonja Groß, Mira Jung, Jeannine Hoepfner, Natalie Weber, Roger Foo, Andreas Pich, Robert Zweigerdt, Theresia Kraft, Thomas Thum, Christian Bär
-
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-19 Pietro Ameri, Valentina Mercurio, Piero Pollesello, Markus S. Anker, Johannes Backs, Antoni Bayes‐Genis, Barry A. Borlaug, Daniel Burkhoff, Sergio Caravita, Stephen Y. Chan, Frances de Man, George Giannakoulas, Aránzazu González, Marco Guazzi, Paul M. Hassoun, Anna R. Hemnes, Cristoph Maack, Brendan Madden, Vojtech Melenovsky, Oliver J. Müller, Zoltan Papp, Soni Savai Pullamsetti, Peter P. Rainer,
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH‐LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH‐LHF, despite the high number of drugs tested so far. This scientific document addresses the
-
Role of stiff atrium in elucidating diastolic dysfunction in Fontan circulation. Letter regarding the article ‘Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-19 Makoto Takei
-
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association Circulation (IF 37.8) Pub Date : 2024-04-18 Richard K. Cheng, Michelle M. Kittleson, Craig J. Beavers, David H. Birnie, Ron Blankstein, Paco E. Bravo, Nisha A. Gilotra, Marc A. Judson, Kristen K. Patton, Leonie Rose-Bovino, on behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing
Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently
-
New insight into air pollution-related cardiovascular disease: an adverse outcome pathway framework of PM2.5-associated vascular calcification Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-18 Ruiyang Ding, Linyuan Huang, Kanglin Yan, Zhiwei Sun, Junchao Duan
Despite the air quality has been generally improved in recent years, ambient fine particulate matter (PM2.5), a major contributor to air pollution, remains one of the major threats to public health. Vascular calcification is a systematic pathology associated with an increased risk of cardiovascular disease. Although the epidemiological evidence has uncovered the association between PM2.5 exposure and
-
Isthmin-1 alleviates cardiac ischemia/reperfusion injury through cGMP-PKG signaling pathway Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-18 Min Hu, Xin Zhang, Can Hu, Zhen-Guo Ma, Sha-Sha Wang, Teng Teng, Xiao-Feng Zeng, Qi-Zhu Tang
Aims Ischemia/reperfusion (I/R) injury is an important complication of reperfusion therapy for acute myocardial infarction, extremely compromising the cardiac benefits of revascularization, however, specific and efficient treatment for cardiac I/R injury is still lacking. Isthmin-1 (ISM1) is a novel adipokine, and plays indispensable roles in regulating glycolipid metabolism and cell survival. The
-
The proprotein convertase FURIN is a novel aneurysm predisposition gene impairing TGF-β signaling Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-18 Zongsheng He, Arne S IJpma, Dianne Vreeken, Daphne Heijsman, Karen Rosier, Hence J M Verhagen, Jorg de Bruin, Hennie T Brüggenwirth, Jolien W Roos-Hesselink, Jos A Bekkers, Danny Huylebroeck, Heleen van Beusekom, John W M Creemers, Danielle Majoor-Krakauer
Aim Aortic aneurysms (AA) frequently involve dysregulation of transforming growth factor β (TGF-β)-signaling in the aorta. Here, FURIN was tested as aneurysm predisposition gene given its role as proprotein convertase in pro-TGF-β maturation. Methods and results Rare FURIN variants were detected by whole-exome sequencing of 781 unrelated aortic aneurysm patients and affected relatives. Thirteen rare
-
Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation Circ. Res. (IF 20.1) Pub Date : 2024-04-17 Wenqi Ma, Kangni Jia, Haomai Cheng, Hong Xu, Zhigang Li, Hang Zhang, Hongyang Xie, Lingfang Zhuang, Ziyang Wang, Yuke Cui, Hang Sun, Lei Yi, Zhiyong Chen, Shengzhong Duan, Motoaki Sano, Keiichi Fukuda, Lin Lu, Fei Gao, Ruiyan Zhang, Xiaoxiang Yan
BACKGROUND:Medial arterial calcification is a chronic systemic vascular disorder distinct from atherosclerosis and is commonly observed in patients with chronic kidney disease, diabetes, and aging individuals. We previously showed that NR4A3 (nuclear receptor subfamily 4 group A member 3), an orphan nuclear receptor, is a key regulator in apo (apolipoprotein) A-IV-induced atherosclerosis progression;
-
Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension Circ. Res. (IF 20.1) Pub Date : 2024-04-16 Néstor de la Visitación, Wei Chen, Jaya Krishnan, Justin P. Van Beusecum, Venkataraman Amarnath, Elizabeth M. Hennen, Shilin Zhao, Mohammad Saleem, Mingfang Ao, Sergey I. Dikalov, Anna E. Dikalova, David G. Harrison, David M. Patrick
BACKGROUND:Hypertension is characterized by CD8+ T cell activation and infiltration into peripheral tissues. CD8+ T cell activation requires proteasomal processing of antigenic proteins. It has become clear that isoLG (isolevuglandin)-adduced peptides are antigenic in hypertension; however, IsoLGs inhibit the constitutive proteasome. We hypothesized that immunoproteasomal processing of isoLG-adducts
-
Buffering Mechanism in Aortic Arch Artery Formation and Congenital Heart Disease Circ. Res. (IF 20.1) Pub Date : 2024-04-15 AnnJosette Ramirez, Christina A. Vyzas, Huaning Zhao, Kevin Eng, Karl Degenhardt, Sophie Astrof
BACKGROUND:The resiliency of embryonic development to genetic and environmental perturbations has been long appreciated; however, little is known about the mechanisms underlying the robustness of developmental processes. Aberrations resulting in neonatal lethality are exemplified by congenital heart disease arising from defective morphogenesis of pharyngeal arch arteries (PAAs) and their derivatives
-
Inhibition of the mPTP and Lipid Peroxidation Is Additively Protective Against I/R Injury Circ. Res. (IF 20.1) Pub Date : 2024-04-15 Arielys Mendoza, Pooja Patel, Dexter Robichaux, Daniel Ramirez, Jason Karch
BACKGROUND:During myocardial ischemia/reperfusion (I/R) injury, high levels of matrix Ca2+ and reactive oxygen species (ROS) induce the opening of the mitochondrial permeability transition pore (mPTP), which causes mitochondrial dysfunction and ultimately necrotic death. However, the mechanisms of how these triggers individually or cooperatively open the pore have yet to be determined.METHODS:Here
-
Systolic Blood Pressure and Survival to Very Old Age: Results From the Women’s Health Initiative Circulation (IF 37.8) Pub Date : 2024-04-16 Bernhard Haring, Chris A. Andrews, Kathleen Hovey, Aladdin H. Shadyab, Andrea LaCroix, Lisa Warsinger Martin, Milagros C. Rosal, Lewis H. Kuller, Elena Salmoirago-Blotcher, Nazmus Saquib, Patrick Koo, Deepika Laddu, Marcia L. Stefanick, JoAnn E. Manson, Sylvia Wassertheil-Smoller, Michael J. LaMonte
BACKGROUND:The relationship between systolic blood pressure (SBP) and longevity is not fully understood. We aimed to determine which SBP levels in women ≥65 years of age with or without blood pressure medication were associated with the highest probability of surviving to 90 years of age.METHODS:The study population consisted of 16570 participants enrolled in the Women’s Health Initiative who were
-
Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era Circulation (IF 37.8) Pub Date : 2024-04-12 Felix Gerhardt, Eva Fiessler, Karen M. Olsson, Moritz Z. Kayser, Gabor Kovacs, Henning Gall, H. Ardeschir Ghofrani, Roza Badr Eslam, Irene M. Lang, Nicola Benjamin, Ekkehard Grünig, Michael Halank, Tobias J. Lange, Silvia Ulrich, Hanno Leuchte, Matthias Held, Hans Klose, Ralf Ewert, Heinrike Wilkens, Carmen Pizarro, Dirk Skowasch, Max Wissmüller, Martin Hellmich, Horst Olschewski, Marius M. Hoeper
BACKGROUND:Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term
-
Artificial Intelligence and Machine Learning in Cardiology Circulation (IF 37.8) Pub Date : 2024-04-15 Rahul C. Deo
Seven years ago, I wrote a review in this journal on the state of machine learning in medicine.1 My tenet then was that although numerous medical applications could benefit from machine learning, and the requisites for such models—data and algorithms—were widely present, few examples had made their way into practice. I struggled to find illustrative examples from cardiovascular research, let alone
-
The Urban Environment and Cardiometabolic Health Circulation (IF 37.8) Pub Date : 2024-04-15 Sanjay Rajagopalan, Armando Vergara-Martel, Jeffrey Zhong, Haitham Khraishah, Mikhail Kosiborod, Ian J. Neeland, Jean-Eudes Dazard, Zhuo Chen, Thomas Munzel, Robert D. Brook, Mark Nieuwenhuijsen, Peter Hovmand, Sadeer Al-Kindi
Urban environments contribute substantially to the rising burden of cardiometabolic diseases worldwide. Cities are complex adaptive systems that continually exchange resources, shaping exposures relevant to human health such as air pollution, noise, and chemical exposures. In addition, urban infrastructure and provisioning systems influence multiple domains of health risk, including behaviors, psychological
-
Correction to: 2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces Circulation (IF 37.8) Pub Date : 2024-04-15
In the article by Berg et al, “2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces,” which published ahead of print on November 9, 2023, and appeared
-
Correction to: Toward Heart-Healthy and Sustainable Cities: A Policy Statement From the American Heart Association Circulation (IF 37.8) Pub Date : 2024-04-15
In the article by Rajagopalan et al, “Toward Heart-Healthy and Sustainable Cities: A Policy Statement From the American Heart Association,” which published ahead of print on March 4, 2024, and appeared in the April 9, 2024, issue of the journal (Circulation. 2024;149:e1067–e1089. DOI: 10.1161/CIR.0000000000001217), a correction was needed. On page e17, in the Writing Group Disclosures table, in the
-
Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure Circulation (IF 37.8) Pub Date : 2024-04-15
In the article by Wakeham et al, “Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure,” which appeared in the October 13, 2023, issue of the journal (Circulation. 2023;148:2008–2016. doi: 10.1161/CIRCULATIONAHA.123.066170), 2 corrections
-
Correction to: Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts Circulation (IF 37.8) Pub Date : 2024-04-15
In the article by Omiya et al, “Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts,” which appeared in the January 14, 2020, issue of the journal (Circulation. 2020;141:667-677. doi: 10.1161/CIRCULATIONAHA.119.044582), a correction is needed. An overlap was discovered between 2 CD45 and CD68 staining panels for TAC-operated Reg−/− mice in Figure
-
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction JAMA Cardiol. (IF 24.0) Pub Date : 2024-04-17 Ravi B. Patel, Frank E. Silvestry, Jan Komtebedde, Scott D. Solomon, Gerd Hasenfuß, Sheldon E. Litwin, Barry A. Borlaug, Matthew J. Price, Rami Kawash, Scott L. Hummel, Donald E. Cutlip, Martin B. Leon, Dirk J. van Veldhuisen, Andreas J. Rieth, Scott McKenzie, Heiko Bugger, Jeremy A. Mazurek, Samir R. Kapadia, Marc Vanderheyden, Bonnie Ky, Sanjiv J. Shah
ImportanceAlthough the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate
-
Man in His Sixth Decade of Life With Totally Occluded Abdominal Aorta (Leriche Syndrome) JAMA Cardiol. (IF 24.0) Pub Date : 2024-04-17 Karley Fischer, Zuha Nazir, Damian Valencia
This case report discusses a diagnosis of Leriche syndrome in a male patient with peripheral arterial disease, erectile dysfunction, and nonischemic cardiomyopathy.
-
Long‐term efficacy and safety of tailored immunosuppressive therapy in immune‐mediated biopsy‐proven myocarditis: A propensity‐weighted study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Alida Linda Patrizia Caforio, Andrea Silvio Giordani, Anna Baritussio, Davide Marcolongo, Cristina Vicenzetto, Giuseppe Tarantini, Massimo Napodano, Giuseppe Toscano, Dario Gregori, Gloria Brigiari, Patrizia Bartolotta, Elisa Carturan, Monica De Gaspari, Stefania Rizzo, Cristina Basso, Sabino Iliceto, Renzo Marcolongo
AimsStandardized immunosuppressive therapy (IS) had been previously investigated in biopsy‐proven (BP) lymphocytic myocarditis with heart failure (HF). This study evaluated efficacy and safety of tailored IS in BP immune‐mediated myocarditis, irrespective of histology and clinical presentation.Methods and resultsConsecutive BP myocarditis patients treated with long‐term tailored IS on top of optimal
-
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Lawrence A. Leiter, Christopher P. Cannon, Renato D. Lopes, Michael J Davies, Phillip Banks, Bertram Pitt, Ph. Gabriel Steg
-
Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-17 Sebastiaan Dhont, Gitte van den Acker, Tim van Loon, Frederik H. Verbrugge, Jan Verwerft, Sébastien Deferm, Timothy W. Churchill, Wilfried Mullens, Joost Lumens, Philippe B. Bertrand
Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF). Despite this combination being closely associated with unfavourable outcomes, it remains relatively understudied. This is partly due to the inherent heterogeneity of patients with HFpEF. To address this gap, dissecting HFpEF into mechanism‐based phenotypes may offer a promising avenue
-
Ncf1 knockout in SMCs exacerbates angiotensin II-induced aortic aneurysm and dissection by activating the STING pathway Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-17 Hao Liu, Peiwen Yang, Shu Chen, Shilin Wang, Lang Jiang, Xiaoyue Xiao, Sheng Le, Shanshan Chen, Xinzhong Chen, Ping Ye, Jiahong Xia
Aims Aortic aneurysm and dissection (AAD) is caused by the progressive loss of aortic smooth muscle cells (SMCs) and is associated with a high mortality rate. Identifying the mechanisms underlying SMC apoptosis is crucial for preventing AAD. Neutrophil cytoplasmic factor 1 (Ncf1) is essential in reactive oxygen species (ROS) production and SMC apoptosis; Ncf1 absence leads to autoimmune diseases and
-
Mast cells: a novel therapeutic avenue for cardiovascular diseases? Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-17 Remo Poto, Gianni Marone, Stephen J Galli, Gilda Varricchi
Mast cells are tissue-resident immune cells strategically located in different compartments of the normal human heart (the myocardium, pericardium, aortic valve and close to nerves) as well as in atherosclerotic plaques. Cardiac mast cells produce a broad spectrum of vasoactive and proinflammatory mediators, which have potential roles in inflammation, angiogenesis, lymphangiogenesis, tissue remodeling
-
Environmental Exposures and Pediatric Cardiology: A Scientific Statement From the American Heart Association Circulation (IF 37.8) Pub Date : 2024-04-15 Justin P. Zachariah, Pei-Ni Jone, Andrew O. Agbaje, Heather H. Ryan, Leonardo Trasande, Wei Perng, Shohreh F. Farzan, on behalf of the American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Lifestyle and Cardiometabolic Health, and Council on Clinical Cardiology
Environmental toxicants and pollutants are causes of adverse health consequences, including well-established associations between environmental exposures and cardiovascular diseases. Environmental degradation is widely prevalent and has a long latency period between exposure and health outcome, potentially placing a large number of individuals at risk of these health consequences. Emerging evidence
-
Gut bacteria can break down cholesterol Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-04-16 Irene Fernández-Ruiz
A new study identifies a group of gut bacteria that can metabolize cholesterol and are associated with lower plasma cholesterol levels.
-
Body mass index, waist circumference, and mortality in subjects older than 80 years: a Mendelian randomization study Eur. Heart J. (IF 39.3) Pub Date : 2024-04-16 Yuebin Lv, Yue Zhang, Xinwei Li, Xiang Gao, Yongyong Ren, Luojia Deng, Lanjing Xu, Jinhui Zhou, Bing Wu, Yuan Wei, Xingyao Cui, Zinan Xu, Yanbo Guo, Yidan Qiu, Lihong Ye, Chen Chen, Jun Wang, Chenfeng Li, Yufei Luo, Zhaoxue Yin, Chen Mao, Qiong Yu, Hui Lu, Virginia Byers Kraus, Yi Zeng, Shilu Tong, Xiaoming Shi
Background and Aims Emerging evidence has raised an obesity paradox in observational studies of body mass index (BMI) and health among the oldest-old (aged ≥80 years), as an inverse relationship of BMI with mortality was reported. This study was to investigate the causal associations of BMI, waist circumference (WC), or both with mortality in the oldest-old people in China. Methods A total of 5306
-
The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 inhibitors? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Aldostefano Porcari, Marianna Fontana
-
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Mohamed B. Jalloh, Veronica A. Bot, Cristiana Z. Borjaille, Lehana Thabane, Guowei Li, Javed Butler, Faiez Zannad, Christopher B. Granger, Harriette G.C. Van Spall
-
Serum metabolomics improves risk stratification for incident heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-16 Rafael R. Oexner, Hyunchan Ahn, Konstantinos Theofilatos, Ravi A. Shah, Robin Schmitt, Philip Chowienczyk, Anna Zoccarato, Ajay M. Shah
-
Endothelial NLRP3 inflammasome regulation in atherosclerosis Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-16 Shuai Guo, Litao Wang, Kaixiang Cao, Ziling Li, Mingchuan Song, Shuqi Huang, Zou Li, Cailing Wang, Peiling Chen, Yong Wang, Xiaoyan Dai, Xianglin Chen, Xiaodong Fu, Du Feng, Jun He, Yuqing Huo, Yiming Xu
Aim The activation of Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in endothelial cells (ECs) contributes to vascular inflammation in atherosclerosis. Considering the high glycolytic rate of ECs, we delineated whether and how glycolysis determines endothelial NLRP3 inflammasome activation in atherosclerosis. Methods and Results Our results demonstrated a significant
-
ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-16 Bin Liu, Mujahid Azfar, Ekaterina Legchenko, James A West, Shaun Martin, Chris Van den Haute, Veerle Baekelandt, John Wharton, Luke Howard, Martin R Wilkins, Peter Vangheluwe, Nicholas W Morrell, Paul D Upton
Aims Potential loss-of-function variants of ATP13A3, the gene encoding a P5B-type transport ATPase of undefined function, were recently identified in pulmonary arterial hypertension (PAH) patients. ATP13A3 is implicated in polyamine transport but its function has not been fully elucidated. Here, we sought to determine the biological function of ATP13A3 in vascular endothelial cells and how PAH-associated
-
Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study Eur. Heart J. (IF 39.3) Pub Date : 2024-04-15 Qingui Chen, Nienke van Rein, Tom van der Hulle, Julius C Heemelaar, Serge A Trines, Henri H Versteeg, Frederikus A Klok, Suzanne C Cannegieter
Background and Aims Coexisting atrial fibrillation (AF) and cancer challenge the management of both. The aim of the study is to comprehensively provide the epidemiology of coexisting AF and cancer. Methods Using Dutch nationwide statistics, individuals with incident AF (n = 320 139) or cancer (n = 472 745) were identified during the period 2015–19. Dutch inhabitants without a history of AF (n = 320
-
Meet the First Authors Circ. Res. (IF 20.1) Pub Date : 2024-04-11
Dr Kajsa Arkelius completed her Ph.D. in Experimental Vascular Research from the Applied Neurovascular Research group at the University of Lund, Sweden, under the guidance of Dr Saema Ansar. Her doctoral research primarily focused on developing innovative therapeutic approaches to enhance thrombolysis therapy following ischemic stroke. Currently, Dr Arkelius is a postdoctoral fellow in Neurology at
-
Environmental Exposome and Atrial Fibrillation: Emerging Evidence and Future Directions Circ. Res. (IF 20.1) Pub Date : 2024-04-11 Sojin Youn Wass, Omar Hahad, Zain Asad, Shuo Li, Mina K. Chung, Emelia J. Benjamin, Khurram Nasir, Sanjay Rajagopalan, Sadeer G. Al-Kindi
There has been increased awareness of the linkage between environmental exposures and cardiovascular health and disease. Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting millions of people worldwide and contributing to substantial morbidity and mortality. Although numerous studies have explored the role of genetic and lifestyle factors in the development and progression
-
Correction to: Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery Circ. Res. (IF 20.1) Pub Date : 2024-04-11
In the article by Kim et al, “Circadian Rhythms of the Blood-Brain Barrier and Drug Delivery,” which published in the March 15, 2024 issue of the journal (Circ Res. 2023;134:727-747. doi: 10.1161/CIRCRESAHA.123.323521), a correction was needed. There is an error in Figure 3 where the descriptions of the solid line and the dotted line are inaccurate and have therefore been removed from the figure footnote
-
Blood-based cardiometabolic phenotypes in atrial fibrillation and their associated risk: EAST-AFNET 4 biomolecule study Cardiovasc. Res. (IF 10.8) Pub Date : 2024-04-13 Larissa Fabritz, Winnie Chua, Victor R Cardoso, Christoph Al-Taie, Katrin Borof, Anna Suling, Linda Krause, Shino Kany, Christina Magnussen, Karl Wegscheider, Guenter Breithardt, Harry J G M Crijns, A John Camm, George Gkoutos, Patrick T Ellinor, Andreas Goette, Ulrich Schotten, Ursula-Henrike Wienhues-Thelen, Tanja Zeller, Renate B Schnabel, Antonia Zapf, Paulus Kirchhof
Background Atrial fibrillation (AF) and concomitant cardiometabolic disease processes interact and combine to lead to adverse events such as stroke, heart failure, myocardial infarction, and cardiovascular death. Circulating biomolecules provide quantifiable proxies for cardiometabolic disease processes. Their role in defining subphenotypes of AF is not known. Methods and results This prespecified
-
Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results from the TARGET BP I Randomized Clinical Trial Circulation (IF 37.8) Pub Date : 2024-04-08 David E. Kandzari, Michael A. Weber, Atul Pathak, James P. Zidar, Manish Saxena, Shukri W. David, Roland E. Schmieder, Adam J. Janas, Christoph Langer, Alexandre Persu, Farrell O. Mendelsohn, Koen Ameloot, Malcolm Foster III, Tim A. Fischell, Helen Parise, Felix Mahfoud
Background: Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety and effectiveness of alcohol-mediated RDN has not been formally studied in this indication.Methods: TARGET BP I is a prospective, international, sham-controlled, randomized, patient- and assessor-blinded
-
Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial Circulation (IF 37.8) Pub Date : 2024-04-07 Alexander C. Fanaroff, Mitesh S. Patel, Neel Chokshi, Samantha Coratti, David Farraday, Laurie Norton, Charles Rareshide, Jingsan Zhu, Tamar Klaiman, Julia E. Szymczak, Louise B. Russell, Dylan S. Small, Kevin G.M. Volpp
Background: Physical activity is associated with a lower risk of major adverse cardiovascular events, but few individuals achieve guideline recommended levels of physical activity. Strategies informed by behavioral economics increase physical activity, but their longer-term effectiveness is uncertain. We sought to determine the effect of behaviorally-designed gamification, loss-framed financial incentives
-
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis Circulation (IF 37.8) Pub Date : 2024-04-07 Siddharth M. Patel, Yu Mi Kang, KyungAh Im, Brendon L. Neuen, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z.I. Cherney, Brian L. Claggett, Robert A. Fletcher, William G. Herrington, Silvio E. Inzucchi, Meg J. Jardine, Kenneth W. Mahaffey, Darren K. McGuire, John J.V. McMurray, Bruce Neal, Milton Packer, Vlado Perkovic, Scott D. Solomon, Natalie Staplin, Muthiah Vaduganathan, Christoph Wanner
Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.Methods: This was a collaborative trial-level meta-analysis from the SGLT2i meta-analysis cardio-renal trialists consortium, which includes all phase 3, placebo-controlled
-
Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications Eur. Heart J. (IF 39.3) Pub Date : 2024-04-12 Konsta Teppo, K E Juhani Airaksinen, Jussi Jaakkola, Olli Halminen, Birgitta Salmela, Elis Kouki, Jari Haukka, Jukka Putaala, Miika Linna, Aapo L Aro, Pirjo Mustonen, Juha Hartikainen, Gregory Y H Lip, Mika Lehto
Background and Aims Female sex has been linked with higher risk of ischaemic stroke (IS) in atrial fibrillation (AF), but no prior study has examined temporal trends in the IS risk associated with female sex. Methods The registry-linkage Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study included all patients with AF in Finland from 2007 to 2018. Ischaemic stroke rates and rate ratios were
-
Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α Eur. Heart J. (IF 39.3) Pub Date : 2024-04-12 Xingliang Zhou, Yiwei Liu, Yi Shen, Lijun Chen, Wenting Hu, Yi Yan, Bei Feng, Li Xiang, Yifan Zhu, Chenyu Jiang, Zihao Dai, Xu Huang, Liwei Wu, Tianyu Liu, Lijun Fu, Caiwen Duan, Shuhong Shen, Jun Li, Hao Zhang
Background and Aims Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism
-
Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Michael R. Zile, JoAnn Lindenfeld, Fred A. Weaver, Faiez Zannad, Elizabeth Galle, Tyson Rogers, William T. Abraham
AimsCarotid baroreflex activation therapy (BAT) restores baroreflex sensitivity and modulates the imbalance in cardiac autonomic function in patients with heart failure with reduced ejection fraction (HFrEF). We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides long‐term safety and sustainable symptomatic improvement
-
Reply to ‘The pharmacist ally in heart failure: Useful when involved’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-04-12 Craig J. Beavers, Deepak L. Bhatt, Gad Gotter